Genmab A/S Statistics
Share Statistics
Genmab A/S has 635.24M shares outstanding. The number of shares has increased by -2.84% in one year.
| Shares Outstanding | 635.24M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.03% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 635.23M |
| Failed to Deliver (FTD) Shares | 529 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 1.86M, so 0.29% of the outstanding shares have been sold short.
| Short Interest | 1.86M |
| Short % of Shares Out | 0.29% |
| Short % of Float | 0.29% |
| Short Ratio (days to cover) | 1.48 |
Valuation Ratios
The PE ratio is 32.34 and the forward PE ratio is 16.05. Genmab A/S's PEG ratio is 0.2.
| PE Ratio | 32.34 |
| Forward PE | 16.05 |
| PS Ratio | 8.54 |
| Forward PS | 0.5 |
| PB Ratio | 4.45 |
| P/FCF Ratio | 20.09 |
| PEG Ratio | 0.2 |
Enterprise Valuation
Genmab A/S has an Enterprise Value (EV) of -56.30M.
| EV / Earnings | -0.01 |
| EV / Sales | 0 |
| EV / EBITDA | -0.01 |
| EV / EBIT | -0.01 |
| EV / FCF | -0.01 |
Financial Position
The company has a current ratio of 13.34, with a Debt / Equity ratio of 0.
| Current Ratio | 13.34 |
| Quick Ratio | 13.32 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 197.07 |
Financial Efficiency
Return on equity (ROE) is 0.14% and return on capital (ROIC) is 12.69%.
| Return on Equity (ROE) | 0.14% |
| Return on Assets (ROA) | 0.12% |
| Return on Capital (ROIC) | 12.69% |
| Revenue Per Employee | 6.25M |
| Profits Per Employee | 1.65M |
| Employee Count | 2.63K |
| Asset Turnover | 0.47 |
| Inventory Turnover | 3.96 |
Taxes
| Income Tax | 1.28B |
| Effective Tax Rate | 0.23 |
Stock Price Statistics
The stock price has increased by -32.11% in the last 52 weeks. The beta is 0.86, so Genmab A/S's price volatility has been higher than the market average.
| Beta | 0.86 |
| 52-Week Price Change | -32.11% |
| 50-Day Moving Average | 21.5 |
| 200-Day Moving Average | 25.78 |
| Relative Strength Index (RSI) | 56.3 |
| Average Volume (20 Days) | 1.30M |
Income Statement
In the last 12 months, Genmab A/S had revenue of 16.47B and earned 4.35B in profits. Earnings per share was 66.02.
| Revenue | 16.47B |
| Gross Profit | 16.25B |
| Operating Income | 5.32B |
| Net Income | 4.35B |
| EBITDA | 5.56B |
| EBIT | 5.32B |
| Earnings Per Share (EPS) | 66.02 |
Balance Sheet
The company has 14.87B in cash and 770.00M in debt, giving a net cash position of 14.10B.
| Cash & Cash Equivalents | 14.87B |
| Total Debt | 770.00M |
| Net Cash | 14.10B |
| Retained Earnings | 19.02B |
| Total Assets | 39.66B |
| Working Capital | 19.11B |
Cash Flow
In the last 12 months, operating cash flow was 7.38B and capital expenditures -376.00M, giving a free cash flow of 7.00B.
| Operating Cash Flow | 7.38B |
| Capital Expenditures | -376.00M |
| Free Cash Flow | 7.00B |
| FCF Per Share | 107.24 |
Margins
Gross margin is 9.86K%, with operating and profit margins of 3.23K% and 2.64K%.
| Gross Margin | 9.86K% |
| Operating Margin | 3.23K% |
| Pretax Margin | 3.42K% |
| Profit Margin | 2.64K% |
| EBITDA Margin | 33.76% |
| EBIT Margin | 32.3% |
| FCF Margin | 42.52% |
Dividends & Yields
GMAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 307.64% |
| FCF Yield | 51.37% |
Analyst Forecast
The average price target for GMAB is $49, which is 128.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $49 |
| Price Target Difference | 128.3% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on May 1, 2018. It was a forward split with a ratio of 5:1.
| Last Split Date | May 1, 2018 |
| Split Type | forward |
| Split Ratio | 5:1 |
Scores
| Altman Z-Score | 3.3 |
| Piotroski F-Score | 5 |